Overview

LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The objective of this protocol is to confirm the efficacy and safety profile of Lantus in every day medical practice, in type 2 diabetic patients, have been treated with any other insulin but who did not reach the target of A1c = 7%.
Details
Lead Sponsor:
Sanofi
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc